

Viemed Healthcare, Inc. (VMD)

Nasdaq; healthcare; SIC 8090, Services-Misc Health & Allied Services, NEC; CIK 0001729149

Viemed Healthcare, Inc. VMD; healthcare	
Grade	A A B C D E strongest fifth of 371 graded peers percentile 9.7; sampling error 2.5 points; lower is stronger
Rank	37 of 371
Profitability	A/B percentile 21.9
Solvency	C percentile 51.4
Growth and financing	B percentile 28.5
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$199.2M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress, fortress balance sheet
Inputs computable	10 of 14
Graded from	filings received through Mar 4, 2026 219 days before the rescan; latest periodic filing 10-Q received Aug 3, 2026
Last close	\$9.41 2026-10-08; market equity \$358.4M
Price used in grade	None



A, the bull

strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: A from Mar 21, 2023, B from Mar 21, 2024, A from Mar 21, 2025

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 4, 2026

Viemed Healthcare, Inc. (the "Company" or "Viemed"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Viemed's primary objective is to drive growth by

increasing the number of patients served and the level of care provided through its technology-enabled, home-based clinical care and chronic disease management model.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 21.9						
Gross profitability		78.1%	32.2%	10.8	372	2025-12-31
Return on invested capital		not computable	9.3%		one or more	required annual facts are missing
Accruals ratio		(19.7%)	(6.6%)	22.2	811	2025-12-31
Gross margin stability, five years		1.8 pts	2.8 pts	32.6	243	2025-12-31
Solvency, sleeve percentile 51.4						
Twelve-month failure probability		not computable	0.07%		latest	liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		5.38	(0.31)	17.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x		one or more	required annual facts are missing
Interest coverage		not computable	(4.51x)		one or more	required annual facts are missing
Current ratio		1.18x	2.96x	85.7	839	2025-12-31
Growth and financing, sleeve percentile 28.5						
Revenue growth, three-year compound		24.9%	10.0%	26.3	415	2025-12-31
Free cash flow growth, three-year compound		35.0%	10.9%	29.5	96	2025-12-31
Reinvestment rate		20.1%	37.1%	58.3	104	2025-12-31
Asset growth, three years		19.4%	2.1%	21.5	704	2025-12-31
Net share issuance, one year		(2.3%)	2.5%	6.8	634	2026-02-20

Among 371 peers

healthcare; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
32	Veracyte, Inc. (VCYT)	8.4	A	
33	Alkermes plc. (ALKS)	8.6	A	

34	Si-Bone, Inc. (SIBN)	8.9	A	fortress
				balance sheet
35	Viridian Therapeutics, Inc.\DE (VRDN)	9.2	A	dilution,
				fortress
				balance sheet
36	Xtant Medical Holdings, Inc. (XTNT)	9.5	A	fortress
				balance sheet
37	Viemed Healthcare, Inc. (VMD) <	9.7	A	
38	LivaNova plc (LIVN)	10.0	A	fortress
				balance sheet
39	TransMedics Group, Inc. (TMDX)	10.3	A	
40	TG Therapeutics, Inc. (TGTX)	10.5	A	
41	Niagen Bioscience, Inc. (NAGE)	10.8	A	
42	BridgeBio Pharma, Inc. (BBIO)	11.1	A	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	30.2%	8.0%	65
Distance from 52-week high	(23.7%)	(31.4%)	61
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	3.3%	(1.0%)	71
Book value to price	0.40	0.28	62
Sales to price	0.75	0.31	77
Composite equity issuance, five years	(3.8%)	20.3%	21
Relative strength against the sector, log excess return	0.05	(0.14)	65

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$10.7M
Operating cash flow, four quarters	\$60.8M
Months of runway	not finite
Days since last periodic filing	67 (10-Q received Aug 3, 2026)
Median daily dollar volume, 63 sessions	\$3.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$155.5M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
2	assets	us-gaap:Assets	\$199.2M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
3	net income	us-gaap:NetIncomeLoss	\$14.9M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$51.9M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
5	assets	us-gaap:Assets	\$177.1M	2024-12-31	2026-03-04	10-K	0001729149-26-000009
6	revenue	us-gaap:Revenues	\$270.3M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
7	gross profit	us-gaap:GrossProfit	\$133.2M	2024-12-31	2026-03-04	10-K	0001729149-26-000009

8	revenue	us-gaap:Revenues	\$224.3M	2024-12-31	2026-03-04	10-K	0001729149-26-000009
9	gross profit	us-gaap:GrossProfit	\$112.8M	2023-12-31	2026-03-04	10-K	0001729149-26-000009
10	revenue	us-gaap:Revenues	\$183.0M	2023-12-31	2026-03-04	10-K	0001729149-26-000009
11	gross profit	us-gaap:GrossProfit	\$84.7M	2022-12-31	2025-03-10	10-K	0001729149-25-000056
12	revenue	us-gaap:Revenues	\$138.8M	2022-12-31	2025-03-10	10-K	0001729149-25-000056
13	gross profit	us-gaap:GrossProfit	\$73.4M	2021-12-31	2023-03-02	10-K	0001729149-23-000040
14	revenue	us-gaap:Revenues	\$117.1M	2021-12-31	2023-03-02	10-K	0001729149-23-000040
15	current assets	us-gaap:AssetsCurrent	\$48.5M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
16	current liabilities	us-gaap:LiabilitiesCurrent	\$41.1M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$102.9M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
18	operating income	us-gaap:OperatingIncomeLoss	\$22.9M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
19	book equity	us-gaap:StockholdersEquity	\$141.5M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
20	liabilities	us-gaap:Liabilities	\$55.6M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$40.0M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$39.1M	2024-12-31	2026-03-04	10-K	0001729149-26-000009
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$37.8M	2024-12-31	2026-03-04	10-K	0001729149-26-000009
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$45.2M	2023-12-31	2026-03-04	10-K	0001729149-26-000009
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$26.1M	2023-12-31	2026-03-04	10-K	0001729149-26-000009
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$27.7M	2022-12-31	2025-03-10	10-K	0001729149-25-000056
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$22.9M	2022-12-31	2025-03-10	10-K	0001729149-25-000056
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$28.6M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$14.8M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
30	income tax	us-gaap:IncomeTaxExpenseBenefit	\$6.4M	2025-12-31	2026-03-04	10-K	0001729149-26-000009
31	current assets	us-gaap:AssetsCurrent	\$52.9M	2024-12-31	2026-03-04	10-K	0001729149-26-000009
32	current liabilities	us-gaap:LiabilitiesCurrent	\$37.3M	2024-12-31	2026-03-04	10-K	0001729149-26-000009
33	assets	us-gaap:Assets	\$154.9M	2023-12-31	2025-03-10	10-K	0001729149-25-000056
34	assets	us-gaap:Assets	\$117.0M	2022-12-31	2024-03-06	10-K	0001729149-24-000077
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	38,602,631	2026-02-20	2026-03-04	10-K	0001729149-26-000009
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	39,521,618	2025-02-18	2025-03-10	10-K	0001729149-25-000056